HURA: 2024 Financial Results [Yahoo! Finance]
TuHURA Biosciences, Inc. (HURA)
Company Research
Source: Yahoo! Finance
On April 1 st , 2025, TuHURA Biosciences, Inc. (NASDAQ:HURA) reported 2024 financial and operational results and filed its Form 10-K with the SEC. TuHURA provided updates on its Phase III trial in Merkel cell carcinoma (MCC), the acquisition of Kineta and introduced a new board member and executive. Initiation of the Phase III IFx-2.0 study in MCC is expected to begin in 2Q:25 and the acquisition of Kineta is targeted for 2Q:25. Below, we summarize 2024's financial results. TuHURA generated no revenues in 2024 and expended $17.6 million on operational activities related to advancing IFx-2.0 and other programs producing a net loss of ($21.7) million or ($1.16) on a per share basis. For the year ending December 31 st , 2024 and versus the same prior year period: Research & development expense totaled $13.3 million, up 42% from $9.4 million, primarily attributable to an increase in spending on the IFx-2.0 program, additional preclinical research for the IFx-3.0 and myeloid derived s
Show less
Read more
Impact Snapshot
Event Time:
HURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HURA alerts
High impacting TuHURA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
HURA
News
- TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone [Yahoo! Finance]Yahoo! Finance
- TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual MilestonePR Newswire
- TuHURA Biosciences (NASDAQ:HURA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=HURA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- TuHURA Biosciences Provides Corporate Update Following Recent Financing [Yahoo! Finance]Yahoo! Finance
- TuHURA Biosciences Provides Corporate Update Following Recent FinancingPR Newswire
HURA
Earnings
- 11/14/25 - Beat
HURA
Analyst Actions
- 11/14/25 - Maxim Group
HURA
Sec Filings
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- 12/10/25 - Form 8-K
- HURA's page on the SEC website